Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuanyin Ning Formula and Bevacizumab for Malignant Pleural Effusion
NCT07670338Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jun 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Randomised, double-blind trial in malignant pleural effusion (MPE) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Objective Response Rate of pleural effusion at 12 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT07670338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670338.